A phase I study of conbination therapy with intratumorak administration of dendritic cells and radiation for far advanced esophageal cancer

A phase I study of conbination therapy with intratumorak administration of dendritic cells and radiation for far advanced esophageal cancer - Chiba RT-DC therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012218

Enrollment

Registered

2013-11-05

Start date

2013-11-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Radition Dendritic cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histrogically proven esophageal squamous cell carcinoma 2.Standard-treatment-failured cases 3.Measurable cases to which no radiation is administered 4.age 20 and more, 74 and less 5.PS0-1 6.4 weeks of more has been past after prior treatment 7. 2 months or more of survival can be estimated 8. Adequate organ functions 9. Written informed consent

Exclusion criteria

Exclusion criteria: 1. History of radiotherapy or immunotherapy 2. tumor has fistula 3. obvious infection 4. hypoalbuminemia 5. uncontrorable pleural effusion or ascites 6. severe heart failure 7. other complications (ileus, pneumonitis, pleural fibrosis, DM, renal failure, liver cirrhosis) 8. Psychologic diorders 9. double cancers 10. steroid administration

Design outcomes

Primary

Measure	Time frame
Evaluation of safety	—

Secondary

Measure	Time frame
Tumor response, Evalustion of immunoresponse	—

Countries

Japan

Contacts

Public ContactYasunori Akutsu

Chiba University Department of Frontier Surgery

yakutsu@faculty.chiba-u.jp043-226-2110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026